Survodutide da Tirzepatide: Yaya Suke Kwatanta?

Survodutide da tirzepatide duka magunguna ne da ake allura da su da ake nazari don rage kiba da lafiyar ƙwayar cuta. Babban bambanci shine cewa tirzepatide FDA ta amince da shi kuma yana samuwa, yayin da survodutide har yanzu yana cikin gwaje-gwajen asibiti kuma bai samu ga jama'a ba tukuna. Hakanan suna aiki ta hanyoyi daban-daban na hormone, wanda zai iya zama mahimmanci ga takamaiman manufofin kiwon lafiya.

Idan kuna ƙoƙarin fahimtar yadda waɗannan magungunan guda biyu suke tsayawa, ga abin da binciken ya nuna zuwa yanzu.

Yaya Kowace Magani Ke Aiki?

Dukansu kwayoyi masu kunna abubuwa guda biyu ne, wanda ke nufin suna kunna masu karɓar hormone guda biyu a lokaci ɗaya. Amma ma'auratan masu karɓar da suke niyya daban-daban ne, kuma hakan yana canza yadda suke shafar jikinka.

Tirzepatide tana niyya ga masu karɓar GLP-1 da GIP. GLP-1 (glucagon-like peptide-1) yana rage ci, yana rage saurin cika ciki, kuma yana taimakawa wajen daidaita sukarin jini. GIP (glucose dependent insulinotropic polypeptide) yana inganta fitar da insulin kuma yana iya shafar yadda jikinka ke sarrafa kitse. Tare, waɗannan hanyoyi guda biyu suna haifar da tasiri mai ƙarfi akan sarrafa sukarin jini da rage kiba. Ana sayar da Tirzepatide a ƙarƙashin sunayen kamfani Mounjaro (don ciwon sukari na 2) da Zepbound (don sarrafa kiba).

Survodutide tana niyya ga masu karɓar GLP-1 da glucagon. Ta dai raba tasirin GLP-1 wanda ke rage ci da tirzepatide, amma maimakon GIP, tana kunna hanyar glucagon. Glucagon yana taimakawa jikinka ƙara yawan kuzarin da ake kashewa da kuma kona kitse da aka ajiye, musamman kitse na hanta. Wannan yana sa survodutide ya zama mai ban sha'awa musamman ga cututtuka kamar MASH (metabolic dysfunction-associated steatohepatitis), nau'in cutar hanta mai kitse.

Don haka tirzepatide tana mai da hankali kan ci tare da alamomin insulin, yayin da survodutide ke mai da hankali kan ci tare da konewar kuzari. Dukansu suna haifar da rage kiba, amma ta hanyoyin da suka bambanta.

Mene Ne Bayanai na Rage Kiba Suke Nuna?

A nan ne mafi yawan mutane ke son amsa mai haske. Dangane da bayanan gwajin asibiti da ake samu, tirzepatide a halin yanzu tana nuna sakamako mafi girma na rage kiba fiye da survodutide.

Babban nazarin shekarar 2022 na mahalarta 2,539 ya gano cewa tirzepatide a kashi na 5 zuwa 15 MG ya samar da 15 zuwa 20.9 bisa dari na rage nauyin jiki bayan makonni 72. Har ma bayan makonni 48, mahalarta sun ga kimanin 14 zuwa 19 bisa dari na rage kiba. Wasu masu amfani a rayuwar gaske sun ba da labarin rasa fiye da kashi 20 na nauyin jikinsu.

Nazarin kiba na survodutide na mataki na 2 ya haɗa da mahalarta 387 kuma ya nuna 6.2 zuwa 14.9 bisa dari na rage kiba a mafi girman kashi bayan makonni 46. Sakamakon mafi girma na kusan kashi 15 na rage kiba yana da ban sha'awa, amma nazarin ya fi guntu kuma ya fi kananan gwaje-gwajen tirzepatide na farko.

Yana da mahimmanci a lura cewa survodutide har yanzu yana cikin gwaje-gwajen mataki na 3. Manyan nazarin da suka daɗe na iya nuna lambobi daban-daban. Amma bisa ga abin da muke da shi a yau, tirzepatide tana bayyana tana samar da babban rage kiba gaba ɗaya.

Yaya Game da Sarrafa Sukar Jini?

Tirzepatide tana da bayanai masu ƙarfi anan. Gwaje-gwajen asibiti sun nuna cewa ta rage HbA1c (auna yawan sukarin jini na tsawon watanni uku) har zuwa 2.4 bisa dari a cikin mutanen da ke da ciwon sukari na 2. Wannan shine ɗayan manyan raguwa da aka gani tare da kowace maganin ciwon sukari ta allura.

Survodutide kuma ta nuna ingantacciyar ci gaba a matakin sukarin jini a cikin gwajin ciwon sukari na mataki na 2. Koyaya, dataset ɗin yana da ƙanƙanta kuma ana tabbatar da sakamakon a manyan nazarin.

Ga mutanen da ke da ciwon sukari na 2 da ke neman zaɓi da aka tabbatar yanzu, tirzepatide tana da tushen shaidar da ta fi ƙarfi.

A INA NE SURVODUTIDE KE DA RUWAN RUWA?

Babban fa'idar survodutide ita ce tasirin mai karɓar glucagon ɗinta, wanda zai iya ba ta fa'idodin da tirzepatide ba ta bayar ba.

Lafiyar hanta. A cikin nazarin mataki na 2 na mutanen da aka tabbatar da MASH da fibrosis na hanta ta hanyar biopsy, kashi 43 zuwa 62 na marasa lafiya da aka yi wa maganin survodutide sun cika manufar hanta ta farko bayan makonni 48, idan aka kwatanta da kashi 14 da na placebo. Kusan kashi 34 zuwa 36 kuma sun nuna ingantacciyar matakin fibrosis aƙalla ɗaya. Waɗannan sakamakon sun haifar da sha'awa sosai saboda MASH a halin yanzu yana da ƴan magunguna masu tasiri.

Yawan kuzarin da ake kashewa. Hanyar glucagon na iya ƙara yawan yanayin metabolism na hutawa, wanda ke nufin jikinka yana cinye ƙarin adadin kuzari ko da a hutu. Wannan wata hanya ce daban da tirzepatide, wanda ke aiki ta hanyar rage abin da kuke ci.

Survodutide ta sami lambobin yabo na FDA Breakthrough Therapy da Fast Track, wanda ke nuna cewa masu tsara doka suna ganin ta a matsayin magani mai mahimmanci ga cututtuka masu tsanani. Sauran gwaje-gwajen mataki na 3 a cikin kiba da MASH suna gudana a halin yanzu.

Yaya Saurin Sakey Sakey Suke Kwatanta?

Dukansu magunguna suna haifar da tasirin gefe na gastrointestinal. Wannan yana zama ruwan dare gama gari a duk azuzuwan kwayoyi masu tushen GLP-1.

Tare da tirzepatide, abubuwan da aka fi bayarwa na gefe sun haɗa da tashin zuciya, gudawa, amai, da maƙarƙashiya. A cikin gwaje-gwajen asibiti, kimanin kashi 4.3 zuwa 7.1 na mahalarta sun daina jinyar saboda tasirin gefe. Yawancin alamun GI sun kasance masu sauƙi zuwa matsakaici kuma suna iya inganta tare da lokaci, musamman tare da karin girman girman girman da aka yi a hankali.

Tare da survodutide, bayanin tasirin gefe yayi kama: tashin zuciya, gudawa, amai, da maƙarƙashiya. Koyaya, a cikin nazarin ciwon sukari na mataki na 2, an ba da rahoton cututtukan GI ta kashi 55 na mahalarta survodutide idan aka kwatanta da kashi 22 akan placebo. Yawan daina jinya saboda tasirin gefe ya yi kama da na tirzepatide, kodayake babu bayanan kwatanta kai tsaye.

Dukansu magunguna suna buƙatar ɗaukar kashi a hankali (fara ƙasa da ƙara a hankali) don taimakawa jikinka ya daidaita kuma ya rage tasirin GI.

Wanne Yake Samuwa Yanzu?

Tirzepatide FDA ta amince da shi kuma tana samuwa ta hanyar likita. Tana zuwa cikin shirye-shiryen allura da aka shirya kuma ana allura ta mako-mako a cikin 2.5 MG, 5 MG, 7.5 MG, 10 MG, 12.5 MG, da 15 MG. Inshora na iya rufe shi ƙarƙashin takamaiman yanayi don ciwon sukari na 2 ko sarrafa kiba.

Survodutide ba a amince da ita ko kuma tana samuwa a wajen gwaje-gwajen asibiti ba. Babu jadawalin amincewa tukuna, saboda gwaje-gwajen mataki na 3 suna gudana. Ba za ku iya samun ta ta hanyar likita ko kantin magani a wannan lokacin ba.

Zababben Magana

Tirzepatide ita ce zaɓi da aka tabbatar kuma tana samuwa tare da bayanai masu ƙarfi na rage kiba da sukarin jini. Survodutide ita ce sabuwar magani mai ban sha'awa wacce zai iya bayar da fa'idodin hanta da na motsa jiki ta hanyar tasirin glucagon ɗinta. Idan kuna buƙatar magani yanzu, tirzepatide ita ce zaɓin bayyane. Idan sakamakon mataki na 3 na survodutide ya tabbatar da alkawarinsa na farko, zai iya zama zaɓi mai mahimmanci nan gaba, musamman ga mutanen da ke da cutar hanta mai kitse.